Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease

Postgraduate Medical Journal

Volumn 87, Issue 1032, 2011, Pages 664-669

  Lee, Yu Ji ^a   Cho, Seong ^a   Kim, Sung Rok ^a   Jang, Hye Ryoun ^a   Lee, Jung Eun ^a   Huh, Wooseong ^a   Kim, Dae Joong ^a   Oh, Ha Young ^a   Kim, Yoon Goo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSINOGEN; CREATININE; LOSARTAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; HUMAN; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSINOGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM;

EID: 80053371265     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2011.118059     Document Type: Article

References (33)

1. Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997;52:149-510.
2. Kang Wook L, Jung-Hun S, Min-Kyu K, et al. The role of renin-angiotensin system in progressive renal injury. Korean J Nephrol 2001;20:26-41.
3. Graciano ML, Cavaglieri Rde C, Delle H, et al. Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 2004;15:150-180.
4. Kobori H, Katsurada A, Ozawa Y, et al. Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun 2007;358:15-63.
5. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994;23:24-54.
6. Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994;9:26-9.
7. Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:85-6.
8. Praga M, Andrade CF, Luno J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003;18:13-18.
9. Izuhara Y, Nangaku M, Inagi R, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005;16:341-363.
10. Baltatu O, Silva JA Jr, Ganten D, et al. The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy. Hypertension 2000;35:12-40.
11. Mazzocchi G, Malendowicz LK, Markowska A, et al. Role of adrenal renin-angiotensin system in the control of aldosterone secretion in sodium-restricted rats. Am J Physiol Endocrinol Metab 2000;278:E102-30.
12. Danser AH, Admiraal PJ, Derkx FH, et al. Angiotensin I-to-II conversion in the human renal vascular bed. J Hypertens 1998;16:205-6.
13. Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:25-87.
14. Kobori H, Prieto-Carrasquero MC, Ozawa Y, et al. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 2004;43:112-32.
15. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002;61:57-85.
16. Kobori H, Nishiyama A, Harrison-Bernard LM, et al. Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension 2003;41:4-9.
17. Yamamoto T, Nakagawa T, Suzuki H, et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007;18:155-65.
18. Kobori H, Harrison-Bernard LM, Navar LG. Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension 2001;37:132-35.
19. Klett C, Nobiling R, Gierschik P, et al. Angiotensin II stimulates the synthesis of angiotensinogen in hepatocytes by inhibiting adenylylcyclase activity and stabilizing angiotensinogen mRNA. J Biol Chem 1993;268:25095-25107.
20. Kobori H, Alper AB Jr, Shenava R, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 2009;53:34-50.
21. Urushihara M, Kondo S, Kagami S, et al. Urinary angiotensinogen accurately reflects intrarenal renin-angiotensin system activity. Am J Nephrol 2010;31:25-31.
22. Ruggenenti P, Perna A, Mosconi L, et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 1998;53:120-126.
23. Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005;165:53-94.
24. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 1996;11:46-7.
25. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:62-75.
26. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:3-48.
27. Tomino Y, Kawamura T, Kimura K, et al. Antiproteinuric effect of olmesartan in patients with IgA nephropathy. J Nephrol 2009;22:22-31.
28. Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006;47:60-75.
29. Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007;27:28-93.
30. Navar LG, Harrison-Bernard LM. Intrarenal angiotensin II augmentation in angiotensin II dependent hypertension. Hypertens Res 2000;23:29-30.
31. Kobori H, Ohashi N, Katsurada A, et al. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2008;2:34-54.
32. Jang HR, Kim SM, Lee YJ, et al. The origin and the clinical significance of urinary angiotensinogen in proteinuric IgA nephropathy patients. Ann Med 2011. (Epub).
33. Moriyama T, Kitamura H, Ochi S, et al. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 1995;6:167-8.